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ABSTRACT
Steviol glycosides are natural constituents of Stevia rebaudiana
(Bert.) Bert. (Asteraceae) that have recently gained worldwide ap-
proval as nonnutritive sweeteners by the Joint Food and Agriculture
Organization/World Organization Expert Committee on Food Ad-
ditives. Cheminformatic tools suggested that the aglycone steviol
and several of its phase I metabolites were predicted as potential
anticonvulsant agents effective in the seizure animal model max-
imal electroshock seizure (MES) test. Thus, aqueous infusion from
S. rebaudiana was tested in the MES test (mice, intraperitoneal
administration), confirming dose-dependent anticonvulsant effect.
Afterward, isolated stevioside and rebaudioside A were tested in the
MES test, with positive results. Though drug repositioning most
often focuses on known therapeutics, this article illustrates the
possibilities of this strategy to find new functionalities and thera-
peutic indications for food constituents and natural products.
INTRODUCTION
D
rug repositioning refers to finding new therapeutic
indications for already-known drugs.1 Such
strategy has recently raised much interest within
the international drug development community,
including a number of public programs to promote reposition-
ing launched by national health authorities in developed
countries such as the United States and United Kingdom.2,3
Since already-known drugs have already undergone safety as-
sessment and pharmacokinetic characterization, repositioning
often allows acceding clinical trials early in the drug discovery
process, speeding up the development of novel therapeutics.
Though drug repositioning often focuses on previously
known therapeutics, it also presents great potential to identify
novel functionalities and therapeutic applications of food
constituents.
We have recently identified, through cheminformatic tools,
the anticonvulsant activity of artificial sweeteners ace-
sulfame, cyclamate, and saccharin.4 These positive results led
us to wonder whether natural sweeteners also have anticon-
vulsant effects. Natural products (NP) remain one of the most
important sources of lead structures in the drug discovery
field. About 30% of the small-molecule new approved drugs
introduced to the market between 1981 and 2002 were NP or
NP derivatives (without considering peptides or proteins ob-
tained from organisms and cell lines by biotechnological
means).5 Furthermore, NPs present high chemical diversity
and a large overlap in chemical space with approved drugs.6,7
Stevia, a member of the Asteraceae family, is a plant native
to South America; extracts of the leaves of the stevia plant
have a long traditional use to sweeten food and beverages in
Argentina, and have also been used for several years in Japan
and China and some European countries.8,9 Very recently,
stevia was approved for use as a sweetener by the Joint Food
and Agriculture Organization World Organization Expert
Committee on Food Additives.10
Here we report the application of ligand-based computa-
tional models to predict whether stevia constituents and/or
their phase I metabolites might have anticonvulsant proper-
ties. Afterward, an aqueous infusion of stevia leaves and
isolated steviosides was tested in seizure models (mice, in-
traperitoneally [ip]) to confirm our predictions.
MATERIALS AND METHODS
Prediction of Stevia Constituents’
Anticonvulsant Activity
Two independent and previously reported ligand-based
computational models were used to predict the potential an-
ticonvulsant effect of stevia constituents and their phase I
DOI: 10.1089/adt.2015.29010.meddrrr ª MARY ANN LIEBERT, INC.  VOL. 13 NO. 6  JULY/AUGUST 2015 ASSAY and Drug Development Technologies 313
metabolites (Fig. 1) in the maximal electroshock seizure
(MES) test.
The first model applied to screen the stevia constituents
was a four-feature linear classificatory model based on
conformation-independent topological molecular descrip-
tors and information indices.11 The molecular descriptors
included in this model were computed with Dragon Soft-
ware for molecular descriptors calculation v. 4. 0 (Milano
Chemometrics, 2003). The model consists of four molecular
descriptors:
Class = 8:110 - (2:206 · HVcpx) - (4:277 · BIC2) + (0:443
· GATS7e) + (1:089 · GATS8p)
where a positive value of the model’s response (Cxlass) is linked
to anticonvulsant effect in the MES test, while a negative
value is associated to lack of anticonvulsant effect. HVcpx
denotes the graph vertex com-
plexity index, BIC2 stands for
the bond information content
(neighborhood symmetry of sec-
ond order), GATS7e symbol-
izes Geary autocorrelation lag 7,
weighted by atomic Sanderson
electronegativities, and GATS8p
denotes Geary autocorrelation
lag 8, weighted by atomic polar-
izabilities.
HVcpx and BIC2 belong to
a group of topological indices
known as information indices,
which are obtained by combin-
ing graph theory and Shannon’s
information theory.12 Informa-
tion indices provide information
on the local or global complex-
ity of the molecule. For exam-
ple, HVcpx reflects the average
vertex complexity; the vertex
complexity vci is computed from
the topological distance matrix
as follows13:




The previous sum runs from
zero to the vertex eccentricity
ecc(vi); pg is the probability of
randomly selecting a distance
equal to g from the considered
vertex/atom. A completely sym-
metric vertex is associated to a
low vertex complexity. Thus, the
inclusion of these information
indices in the model may reflect
the relatively simpler molecular
topology of the anticonvulsants
Fig. 1. Chemical structures of the constituents of stevia (and some phase I metabolites) screened
with our computational models.
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used to train the model compared to compounds from other
therapeutic categories included as training instances in the
inactive class.
Regarding Geary autocorrelations, they describe the distri-
bution of a given atomic property in the molecule. These in-
dices will assume larger values when the considered molecule
includes atoms with differences in the atomic property under
consideration (electronegativity, polarizability) at the topo-
logical distance examined (the lag). The model might be re-
flecting that (1) anticonvulsants, compared to the inactive
compounds included in the training set, tend to possess rather
compact structures, and thus anticonvulsants present less pairs
of atoms separated by long interatomic distances, and (2) anti-
convulsants tend to present, in their molecular structure, one or
two polar regions, with the other part of the molecule being
rather hydrophobic, in contrast with drugs from other thera-
peutic categories presenting a more uniform charge distribution.
The second model is a Sybyl pharmacophore obtained
through the active analog approach that proposes the geomet-
rical arrangement of hydrophobic and polar moieties required to
elicit the protective effects in the MES test.14 Such model has
been derived from the superposition of the rigid anticonvulsants
phenytoin and carbamazepine, and was later refined through the
alignment of 15 additional drugs active in the MES test with the
common capability of blocking voltage-gated sodium channels.
The common pattern emerging from such alignment includes a
hydrophobic chain (atoms5–7; Fig. 2) and a polar moiety (atoms
1–3; Fig. 2). The hydrophobic chain is usually (though not
necessarily) of aromatic nature. Whereas some of the anticon-
vulsant compounds used to infer the pharmacophore show two
hydrophobic regions, a single hydrophobic tail is present inother
compounds, this being the minimum structural requisite.
Pharmacophore superposition was conducted with Hy-
perchem v. 8.0 (Hypercube, 2007). To that purpose, Hy-
perchem’s Conformational Search module was used with the
PM3 optimization method and an RMS gradient of 0.05 kcal/
(Å$mol). At least 250 optimizations were performed; optimi-
zations were conducted until convergence (i.e., until no new
low-energy conformers are found). The lowest energy con-
former of each drug was then superposed onto the pharma-
cophore, and the energy difference (conformational strain
energy) between the lowest energy conformer and the con-
former that approach the most to the pharmacophore con-
formation was calculated for each molecule. In other words,
an induced fit onto the pharmacophore was performed using
the lowest energy conformer, and the energy difference be-
tween the bioactive conformation and the minimum energy
conformer was computed. RMS for the superposition of the
minimum energy conformer and the pharmacophore (RMS 1)
and the induced conformer and the pharmacophore (RMS 2)
were also calculated. It is worth highlighting that these two
models have previously been jointly applied to screen NP li-
braries, with good results.15
Plant Material and Preparation of Extracts
Authenticated stevia [Stevia rebaudiana (Bert.) Bert.] plants
from ecological crops were field-grown in La Capilla, Partido
Florencio Varela, Buenos Aires Province, Argentina (34 550
43† S–58 160 29† W). A voucher specimen was deposited in
Exact Sciences Faculty, Carlos Spegazzini Museum, UNLP,
Argentina (LPE 1163). The leaves were harvested in early
summer (Nov–Dec 2012) from fully grown shoots, air-dried at
room temperature, and ground. Powdered drug (20 g) was ex-
tracted by infusion and lyophilized (yield: 34.98%). For further
enrichment of the diterpene glycosides, the extract (20 mL) was
shaken with 20mL n-butanol, and the n-butanol phase was
separated, evaporated to 3 mL, and used for TLC. An amount of
20mL was spotted on precoated silicagel 60 F254 plates
(0.25mm thick; E. Merck, Darmstadt) and developed with
chloroform–methanol–water (65:25:4). After development,
chromatograms were air-dried, sprayed with Liebermann-
Bouchard reagent, and heated for 5–10min at 110C (evalua-
tion: vis and UV366). The chromatographic profile of the stevia
folia extract shows nine gray zones, distributed over the whole
Rf range. Four of them are found in the Rf range 0.1–0.3. Ac-
cording to bibliographical data, the zones at Rf 0.2 and 0.3
correspond to rebaudioside A and stevioside, respectively.16
Anticonvulsant Preclinical Screening
The evaluation of the anticonvulsant activity was per-
formed by following the anticonvulsant drug development
program of the National Institutes of Health. Adult male Swiss
mice (18–23 g) were used as experimental animals. Animals of
Fig. 2. Sybyl pharmacophore. Atoms 1–3 represent a polar moiety;
atoms 5–7 represent a hydrophobic tail.
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the same age and weight have been selected in order to
minimize biological variability. The animals were maintained
on a 12-hour light/dark cycle and allowed free access to food
and water, except during the time they were removed from
their cages for testing. Mice received a daily administration of
saline (0.1 mL ip) for 1 week. This procedure allows the ani-
mals to habituate to manipulation, avoiding downregulation
of GABA receptors induced by acute handling, which could
affect the susceptibility to convulsions.17
The dry aqueous infusion from S. rebaudiana was properly
dissolved in water in all the cases, without solubility problems.
A maximal volume of 5 mL/kg of the freshly made solutions
was injected ip to groups of two to four mice, at doses of 30
and 100 mg/kg. MES were elicited in mice by delivering a
60 Hz/50 mA electrical stimuli for 0.2 s via ear clip electrodes,
at 0.5 and 4 hours after the drug injection, using an UGO Basile
equipment. A drop of saline was applied on each ear before
placing the electrodes to ensure adequate electrical contact. In
these conditions, maximal seizures are produced in virtually
all normal mice. The maximal seizure typically consists of a
short period of tonic flexion followed by a longer period of
tonic extension of the hind limbs and a final clonic episode.
Blockade of the hind limbs tonic extension due to the drug
treatment is taken as the end point. The tonic component is
considered abolished if the hind leg tonic extension does not
exceed a 90 angle with the trunk. The rotorod test was used to
determine possible neurotoxic effects of the test drugs. Con-
trol animals are manipulated as described above except that
they receive vehicle (saline) instead of the drug solution.
Quantitative studies were conducted at 4 hours, which was
the time at which maximal anticonvulsant effect was ob-
served, as shown in the Results and Discussion section. The
ED50 was determined by treating groups of six albino mice.
The method of Litchfield and Wilcoxon was used to compute
the ED50 value.18
The isolated steviosides were tested as described in the
previous paragraphs. Rebaudioside A was acquired from
Sigma Aldrich. Stevioside was a gentle gift from Prof. Kolb
Kozlobsky, Faculty of Exact Sciences, National University of
Misiones. It was obtained through preparative chromatogra-
phy, and selected fractions were collected and purified. The
compounds in each sample were identified by isocratic HPLC,
comparing their retention times with those of the reference
compounds, according the Kolb et al.’s method.19
RESULTS AND DISCUSSION
Our models predicted that steviol and all its phase I me-
tabolites tested would have anticonvulsant activity. Table 1
shows the output of the linear classificatory model for these
compounds; the values of the molecular descriptors for stevia
components and its derivatives are also presented. Table 2
shows the strain energy and RMS values correspondent to the
superposition with the pharmacophore. Steviosides were
predicted as non-anticonvulsants in the MES test. Super-
position of steviol on the pharmacophore model is presented
in Figure 3. The conformational strain energy for steviol and
its metabolites was, in all cases, below 5 kcal/mol, which in-
dicates that steviol and its metabolites can probably assume a
conformation similar to those of the active rigid analogs from
which our pharmacophore was inferred.20
Table 1. Model Parameters and Output for the Stevia
Components and Metabolites for the Classificatory
Linear Model
Mol ID HVcpx BIC2 GATS7e GATS8p Class Prediction
15-Hydroxisteviol 2.82 0.67 1.20 0.64 0.27 Anticonvulsant
15-Oxosteviol 2.82 0.65 1.29 0.64 0.39 Anticonvulsant
a-Epoxisteviol 2.83 0.62 1.39 0.62 0.53 Anticonvulsant
Dulcosido A 4.00 0.64 0.96 1.01 - 1.93 Inactive
Isoesteviol 2.81 0.58 1.29 0.60 0.66 Anticonvulsant
Rebaudioside A 4.05 0.61 0.98 1.03 - 1.89 Inactive
Rebaudioside B 3.73 0.64 1.04 0.97 - 1.36 Inactive
Rebaudioside C 4.05 0.62 0.98 1.02 - 1.92 Inactive
Steviol 2.81 0.62 1.29 0.60 0.48 Anticonvulsant
Steviolbioside 3.65 0.68 0.97 0.96 - 1.37 Inactive
Stevioside 4.01 0.64 0.96 1.02 - 1.91 Inactive
Table 2. Strain Energy and RMS Values from













mol) RMS 1 RMS 2
15-Hydroxysteviol - 5414.86 - 5411.67 3.19 0.8767 0.6030
15-Oxosteviol - 5297.74 - 5295.02 2.72 0.6135 0.4433
Steviol - 5314.60 - 5312.23 2.37 0.8491 0.5533
Isosteviol - 5333.51 - 5333.31 0.20 0.4257 0.4060
a-Epoxisteviol - 5396.37 - 5394.87 1.50 0.6327 0.6046
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On the basis of these results, we decided to evaluate the
pharmacological effect of an aqueous infusion of stevia leaves
in the MES test. Initial results confirmed the anticonvulsant
activity of the infusion, which later proved to be dose de-
pendent (Tables 3 and 4), with an estimated ED50 of 70.3 mg/kg
(47.4–104.3) (mice, ip, 4 hours). Neither of the tested doses
presented neurotoxicity in the rotorod test. Quantitative studies
with stevia aqueous extract were conducted at 4 hours. The
ED50 was determined by treating groups of six albino mice.
Different doses were used for each drug at the time of peak
effect. The method of Litchfield and Wilcoxon was used to
compute the ED50 value.
Having confirmed the anticonvulsant effect of the aqueous
extract from stevia leaves, we decided to test the isolated
stevioside and rebaudioside A, using a similar protocol to the
previously described for the aqueous infusion. Both drugs
showed protective effect in the preclinical testing model. The
results are presented in Table 5.
Noteworthy, the isolated steviosides presented anticon-
vulsant properties in mice, though our models suggested that
they do not have intrinsic activity. This may reflect a mis-
prediction of the model or, alternatively, the model might be
correct and the steviosides may have no intrinsic anticon-
vulsant activity, in which case the anticonvulsant effect could
be attributed to the aglycone and/or its metabolization
products (which are predicted as anticonvulsants). This ap-
pears to be in agreement with the fact that, at 30 mg/kg (the
lower doses tested), stevioside only shows anticonvulsant ef-
fects at 4 hours (presumably, after metabolization to steviol
has taken place). At higher doses (100 mg/kg), the effect at 0.5
hours is higher than that at 4 hours (it should be taken into
consideration that biotransformation frequently follows first-
order kinetics; therefore, the higher the dose the sooner that
the metabolization product might reach effective blood lev-
els). Further studies (e.g., binding studies) are needed to con-
firm whether the steviosides or their metabolites (as predicted
by our models) are the species responsible for the observed
effect in the MES test. Our results demonstrate not only the
anticonvulsant activity of stevia constituents in mice, but also
the potential of computer-aided drug repositioning to dis-
cover new functionalities of food and NP constituents.
Fig. 3. Superposition of steviol on the pharmacophore model.
Table 3. Anticonvulsant Effect of the Aqueous Infusion
from Stevia Leaves at Doses of 30 and 100 mg/kg
MES testa Neurotoxicityb
Doses
(mg/kg) 0.5 h 4 h 0.5 h 4 h
30 0/3 0/3 0/3 0/3
100 1/3 3/3 0/3 0/3
aNumber of protected animals/number of tested animals.
bNumber of animals presenting motor impairment/number of tested animals.
MES, maximal electroshock seizure.
Table 4. Dose-Dependent Anticonvulsant Effect
of Stevia Infusion in the MES Test
Doses (mg/kg) Time (h) Responsea Deathb
50 4 2/6 0/6
70 4 3/6 1/6
90 4 4/6 0/6
100 4 4/6 0/6
aNumber of protected animals/number of tested animals.
bNumber of dead animals/number of tested animals.
Table 5. Anticonvulsant Effect of Isolated Steviosides
MES testa Neurotoxicityb
Drug Doses (mg/kg) 0.5 h 4 h 0.5 h 4 h
Rebaudioside A 30 0/2 0/2 0/2 0/2
100 2/4 2/4 0/4 0/4
Stevioside 30 0/2 3/4 0/2 0/4
100 3/4 1/4 0/4 0/4
aNumber of protected animals/number of tested animals.
bNumber of animals presenting motor impairment/number of tested animals.
STEVIOSIDES ANTICONVULSANT EFFECT
ª MARY ANN LIEBERT, INC.  VOL. 13 NO. 6  JULY/AUGUST 2015 ASSAY and Drug Development Technologies 317
CONCLUSIONS
S. rebaudiana aqueous extract and isolated natural sweet-
eners stevioside and rebaudioside A present protective effects in
the acute seizure animal model MES (mice, ip). In the case of the
aqueous infusion, such effect was proven to be dose dependent.
These observations complement recent previous reports from
our group that indicate that artificial sweeteners also have anti-
MES effects. These facts lend weight to the hypothesis of a
structural link between sweet taste receptor and any of the
molecular targets of antiepileptic drugs. Our results also con-
firm the potential of computer-aided approaches to discover
new drugs among the NP biodiversity and new therapeutic
indications for food additives or constituents. Further studies
are required to verify whether the results reported here are
significant for application in human therapeutics, taking into
consideration that important differences in steviosides’ me-
tabolisms in rodents and human have been reported.8
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